Project description
Affordable non-drug ADHD treatment at home
Up to now, children and adults suffering from attention deficit with or without hyperactivity disorder (ADHD) could only rely on medication accompanied by a slew of side effects or refuse to take medication. The high number of children in Europe suffering from the disease (2.5 million) and the equivalent estimate of undiagnosed adults calls for a different, non-medication approach. KOALA FOCUS is an affordable at-home treatment using neurofeedback and AI techniques for all ages. Once the clinical trials are approved, customers will buy the hardware through a secure platform by Mensia, the producing company, and pay EUR 40 per session.
Objective
Attention Deficit with/without Hyperactivity Disorders (ADHD) is a neurological disorder with a high societal impact: 2.5 M children are diagnosed, and 2-5 M Adults in Europe are non-diagnosed. 50% children are not medicated mainly due to drug refusal and high rate under medication face adverse effects and treatment rejection. Mensia has developed a revolutionary prototype, Mensia KOALA, to treat ADHD by means of neurofeedback at home and without drugs, using Artificial Intelligence techniques. Our new prototype version “KOALA Focus” aims to be the first affordable Gold Standard Medical Device for Precise Medical Neurofeedback friendly used at home, whatever the patient's age.
Our prototype, currently at TRL6, is a breakthrough innovation thanks to disruptive combination: at home evidence based medical neurofeedback technology, the first reliable non-invasive and precise e-Health Digital Therapeutic, monitoring and treating various types of ATTENTION DEFICITS.
Our business model is based on buy hardware cap via secured eHealth Mensia platform and pay per at home session. The ADHD therapeutic market is estimated to reach €21.5 B by 2024 growing at a CAGR of 6.2%. TOTAL ATTENTION DEFICIT market in Europe worth 5 M individuals. KOALA Focus, once validated by the appropriate clinical trials, can achieve up to 50% of regular prescribers from this addressable market in the EU. Mensia aim to set up a Gold Standard of Good Clinical Practices for Precise Medical Neurofeedback at home, capturing 20% (1 M individuals) of this addressable market: 2,5 M children EU + 2,5 M adults. We estimated that in 5 years (end of Phase 2 project), we will accumulate ~€120 M of Revenues at 40€ /session, accounting for ~5% of the EU market, earning ~€36M profit (ROI of 5.7) while hiring 60 new technical and sales employees.
Fields of science
- natural sciencescomputer and information sciencesartificial intelligence
- medical and health scienceshealth scienceshealth care serviceseHealth
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- social scienceseconomics and businessbusiness and managementbusiness models
- medical and health sciencesbasic medicineneurology
Programme(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
35571 CHANTEPIE
France
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.